Compositions and methods for stem cell growth
The use of TGF-β and Hippo pathway inhibitors in dissociated stem cell cultures enhances cell cluster formation and pluripotency, addressing limitations in three-dimensional cell culture expansion for pancreatic islet therapy.
Patent Information
- Application Number
- PCT/US2025/060542
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-08-29
- Filing Date
- 2025-12-19
- Publication Date
- 2026-06-25
AI Technical Summary
Limited stem cell expansion in three-dimensional cell culture prevents effective implementation of artificial pancreatic islets therapy for diabetes, necessitating improved methods for in vitro stem cell expansion that mimic endogenous pancreatic islet function and characteristics.
Compositions and methods involving TGF-β pathway inhibitors and/or Hippo pathway inhibitors, without a gel matrix, are used to enhance stem cell expansion, with at least 25% of cells dissociated, and optionally agitated in a bioreactor, using specific inhibitors like Alk5 inhibitor II, A 83-01, and GA-017, and media such as StemScale and DMEM/F12, to increase cell cluster formation and pluripotency.
The methods result in significant increases in cell clusters and pluripotency, with up to 1000% increase in cell clusters and high expression of OCT4 and SOX2, facilitating effective stem cell expansion for pancreatic islet therapy.
Smart Images
Figure US2025060542_25062026_PF_FP_ABST